BZAD-01

BZAD-01 is an antagonist of NR2B subunit-containing NMDA receptors (Ki = 72 nM). It is selective for NR2B subunit-containing NMDA receptors over those containing NR2A subunits in a calcium mobilization assay (IC50s = 47 and >10,000 nM, respectively). Oral administration of BZAD-01 reduces hyperalgesia induced by carrageenan in rats (ED50 = 5.5 mg/kg). BZAD-01 (10 mg/kg) reduces dopaminergic neuron loss in the rat substantia nigra pars compacta and improves measures of ipsilateral curling, ipsilateral head positioning, and beam walking in a rat model of Parkinson's disease induced by the catecholaminergic neurotoxin 6-OHDA (Cay-25330).Formal Name: 4-(trifluoromethoxy)-N-[[2-(trifluoromethyl)phenyl]methyl]-benzenecarboximidamide. CAS Number: 305339-41-7. Molecular Formula: C16H12F6N2O. Formula Weight: 362.3. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: Methanol: Soluble. SMILES: FC(F)(OC1=CC=C(C(NCC2=C(C(F)(F)F)C=CC=C2)=N)C=C1)F. InChi Code: InChI=1S/C16H12F6N2O/c17-15(18,19)13-4-2-1-3-11(13)9-24-14(23)10-5-7-12(8-6-10)25-16(20,21)22/h1-8H,9H2,(H2,23,24). InChi Key: YGOCAMFQDLFNQK-UHFFFAOYSA-N.